Drug Name:
AVAPRO Rx
Generic Name and Formulations:
Irbesartan 75mg, 150mg, 300mg; tabs.
Company:
Sanofi Aventis
Therapeutic Use:
Indications for AVAPRO:
Treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension.
Adult:
300mg once daily.
Children:
Not recommended.
Contraindications:
Concomitant aliskiren in patients with diabetes.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Interactions:
Hyperkalemia with K+ supplements, K+ sparing diuretics, K+-containing salt substitutes. May increase lithium levels; monitor. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.
Pharmacological Class:
Angiotensin II receptor blocker (ARB).
Adverse Reactions:
Diarrhea, dyspepsia, fatigue, orthostatic hypotension; increased BUN, hyperkalemia; rhabdomyolysis (rare).
Metabolism:
Hepatic (CYP2C9); 90% protein bound.
Elimination:
Biliary, renal.
Generic Availability:
YES
How Supplied:
Tabs—30, 90
Indications for AVAPRO:
Hypertension.
Adult:
≥16yrs: 150mg once daily; may increase to 300mg once daily. Or, may add a low dose of diuretic. Salt/volume depletion: initially 75mg once daily.
Children:
Not recommended.
Contraindications:
Concomitant aliskiren in patients with diabetes.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Interactions:
Hyperkalemia with K+ supplements, K+ sparing diuretics, K+-containing salt substitutes. May increase lithium levels; monitor. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.
Pharmacological Class:
Angiotensin II receptor blocker (ARB).
Adverse Reactions:
Diarrhea, dyspepsia, fatigue; increased BUN, hyperkalemia; rhabdomyolysis (rare).
Metabolism:
Hepatic (CYP2C9); 90% protein bound.
Elimination:
Biliary, renal.
Generic Availability:
YES
How Supplied:
Tabs—30, 90
Sign Up for Free e-newsletters
